Pharmaceutical Industry Market Research Reports in North America, May 2013

Company Report: Drug and Medication in The United States for Year 2011

• Company report
• May 2011
• 9 pages
• by Corporation

... Or shared ftf opportunity 2) ims mat 12/10 targeting $23.7 Billion2 of total market valuetargeting $5.5 Billion2 of total market value atacand hct (dec)1 avandia (sept) singulair (aug) plavix (may) lexapro ...

• Industries: Drug and Medication
• Countries: North America, World, United States

Company Report: Clinical Trial in North America for Year 2011

• Company report
• March 2011
• 3 pages

... Management changes clearly addressing its future as a global operating company. Plant capacity being doubled and expected to be in place by late calendar 2012. Yoplait and nestle clinical trials ...

• Industries: Drug Discovery and Development
• Countries: United States, Canada, North America

Company Report: Pharmaceutical in North America for Year 2011

• Company report
• September 2011
• 2 pages

... France news 26 september 2011 pharmaceuticals & biotechnology sanofi rating 2/outperform target price (6 months) +29.8% Eur61.00 Price (23/09/11) eur46.99 Market capitalisation eur63.403Bn ...

• Industries: Pharmaceutical
• Countries: North America

Cardiome Pharma Corp. - Forward Looking Presentation for Year 2011

• Company report
• December 2011
• 18 pages

... clinical trial accounting we record clinical trial expenses relating to service agreements with various contract research organizations, investigators and other service providers which conduct certain ...

• Industries: Drug Discovery and Development
• Countries: United States, North America, Canada

Mylan Inc. - Investment Analysis, December 2011

• Company report
• December 2011
• 8 pages

... To register and download or install any necessary software. About mylan mylan inc. Ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers ...

• Industries: Pharmaceutical
• Countries: United States, North America, World

Company Report: Drug Discovery and Development in North America for Year 2011

• Company report
• March 2011
• 14 pages

... Expected due to a number of factors, including the costs associated with clinical trials, fees from collaborative and license arrangements with third parties and from strategic opportunities. Our cash ...

• Industries: Drug Discovery and Development
• Countries: United States, North America, Canada

Investor presentation: Insulin in Japan for Year 2011

• Company report
• March 2011
• 17 pages

... Or revise any forward-looking statement after the distribution of this document, whether as a result of new information, future events or otherwise. Important drug information Tresiba (insulin degludec ...

• Industries: Drug and Medication
• Countries: Japan, North America, World

Company Report: Drug Discovery and Development in North America for Year 2011

• Company report
• March 2011
• 13 pages

... Future cash requirements may vary materially from those now expected due to a number of factors, including the costs associated with clinical trials, fees from collaborative and license arrangements ...

• Industries: Drug Discovery and Development
• Countries: United States, North America, Canada

Investor presentation: Drug and Medication in India for Year 2011

• Company report
• March 2011
• 13 pages

... Lansoprazole launche n this wee Fondaparinux Usfda inspection Fexofenadine pseudoephedrine (higher strength) litigation gsk alliance : Shipped products to 7 markets Cumulatively filed ~ 95 dossiers till ...

• Industries: Drug and Medication
• Countries: India, World, North America

Company Report: Drug and Medication in North America for Year 2011

• Company report
• March 2011
• 5 pages

• Industries: Drug and Medication
• Countries: Canada, United States, North America

Company Report: Drug Discovery and Development for Year 2011

• Company report
• March 2011
• 14 pages

... To serve the company in a consulting capacity. 5 Clinical development the following table summarizes recent clinical trials and regulatory developments associated with each of our research ...

• Industries: Drug Discovery and Development
• Countries: United States, North America, World

Investor presentation: Drug and Medication for Year 2011

• Company report
• March 2011
• 24 pages
• by Corporation

• Industries: Drug and Medication
• Countries: World, United States, North America

Company Report: Drug and Medication in Germany and North America for Year 2013

• Company report
• April 2013
• 2 pages

• Industries: Drug and Medication
• Countries: Germany, North America, United States

Company Report: Rnai Therapeutics in North America for Year 2012

• Company report
• January 2012
• 12 pages
• by Corporation

... For physiology or medicine. rnai therapeutics, such as "sirnas," require delivery technology to be effective systemically. Tekmira believes its lnp technology represents the most widely adopted delivery ...

• Industries: Therapy
• Countries: United States, Canada, North America

Medidata Solutions Inc. - Company Report for Year 2012

• Company report
• November 2012
• 2 pages
• by Corporation

... Development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept ...

• Industries: Drug Discovery and Development
• Countries: North America

Company Report: Influenza Vaccine for Year 2012

• Company report
• November 2012
• 7 pages

• Industries: Drug and Medication
• Countries: World, North America

Company Report: Drug and Medication in The United States for Year 2012

• Company report
• November 2012
• 22 pages

• Industries: Drug and Medication
• Countries: World, North America, United States

Company Report: Pathology in North America for Year 2012

• Company report
• November 2012
• 3 pages
• by Corporation

... Characterized for safety, consistency and potency. Athersys has forged strategic partnerships with pfizer inc. To develop multistem for inflammatory bowel disease and with rti biologics, inc. To develop cell ...

• Industries: Pathology
• Countries: United States, North America

OncoGenex Pharmaceuticals Inc. - Investment Analysis, December 2012

• Company report
• December 2012
• 3 pages
• by Corporation

... With metastatic bladder cancer, borealis-1, continues to enroll patients throughout the united states, canada and europe. The study aims to enroll approximately 180 patients and is expected to complete patient ...

• Industries: Pathology
• Countries: Canada, United States, North America

Company Report: Pharmacies and Drug Stores for Year 2012

• Company report
• May 2012
• 25 pages

... The increasing number of 90-day chronic scripts filled at retail, we queried respondents as to whether they offer a 90-day supply of chronic medications at retail pharmacies as part of their plan design. Based ...

• Industries: Pharmacies and Drug Stores
• Countries: North America, World

Trius Therapeutics Inc. - Company Report for Year 2012

• Company report
• November 2012
• 2 pages
• by Corporation

• Industries: Pharmaceutical
• Countries: United States, North America

Company Report: Pathology in Australia and North America for Year 2012

• Company report
• May 2012
• 3 pages

... To the company S future. If the marketing of bioniche S bladder cancer drug (urocidin ) Is successful, then the shares at current prices are substantially undervalued. For more on bioniche, see e ...

• Industries: Pathology
• Countries: Canada, Australia, North America

Company Report: Pathology in Australia and North America for Year 2012

• Company report
• May 2012
• 3 pages
• by Market Research Publisher

... To the company S future. If the marketing of bioniche S bladder cancer drug (urocidin ) Is successful, then the shares at current prices are substantially undervalued. For more on bioniche, see e ...

• Industries: Pathology
• Countries: Canada, Australia, North America

Infectious Disease Business in North America and Europe

• Industry report
• November 2010
• 19 pages

... hepatitis c drug in late stage clinical development innovation as our core competences our first product launch is the foundation for transformation to pharma strong pipeline and partners swedish biotech ...

• Industries: Pathology
• Countries: North America, Sweden, Europe

Anti-inflammatory Market in Japan and North America

• Industry report
• October 2010
• 13 pages

... Diagnosis of ra considerations: Disease activity Clinical score Patient S characteristics Risk factors dmards: (mtx) anti-inflammatories: (nsaids) steroids biological dmards: tnf blockers, il-6r blocker ...

• Industries: Drug and Medication
• Countries: Japan, North America, United States

Global Dietary Supplement : Innovation and Technology Trends

• Industry report
• February 2013
• 14 pages

... Report description prebiotic ingredients market for food & beverage, dietary supplements & animal feed - global industry analysis, market size, share, trends, and forecast, 2012 ...

• Industries: Vitamin and Supplement
• Countries: World, North America, Europe

Pharmaceutical Sector in North America

• Industry report
• August 2012
• 36 pages

... Years. In that time, the pharmaceutical industry has played a significant role in transforming the lives of millions and improving human life expectancy globally. But the industry model is challenging, as typically ...

• Industries: Pharmaceutical
• Countries: Canada, United States, North America

Drug and Medication Industry in North America

• Industry report
• October 2011
• 2 pages

... Molecule products to lower volume biologicals and therapeutic vaccines. This changing focus may have contributed significantly to some of the shortages we have been seeing. There are opportunities ...

• Industries: Drug and Medication
• Countries: United States, North America

Pharmaceutical Industry in North America

• Industry report
• September 2012
• 30 pages

... Being familiar with the published literature on pca3 testing for prostate cancer Less than 20% reported that the requirement for a digital rectal exam prior to a urine collection would limit ...

• Industries: Pathology
• Countries: Canada, United States, North America

Prostate Cancer Business (prostate cancer, colorectal cancer, colon cancer) in North America

• Industry report
• June 2012
• 29 pages

... N engl j med;366:981- 90. Multiple studies show that early diagnosis is critical to reduce risk of prostate cancer death 38% relative risk reduction at 11y risk of prostate cancer death ...

• Industries: Pathology
• Countries: Canada, United States, North America